Jun 11, 2021

New antibody therapies may improve diabetic retinopathy and other eye conditions

by: winonaryder

Professor Stephen Anger and Professor Sachidev Sidu took pictures at the Donnelly Center before the COVID-19 pandemic. Credits: University of Toronto

Insulin, a life-saving diabetes drug developed at the University of Toronto 100 years ago, was the first biotherapy and protein to treat the disease. A century later, new biological therapies developed by researchers at the University of Toronto have the potential to reverse the common complications of diabetes.

A team led by Professor Stephen Angers of the Faculty of Pharmaceutical Sciences Leslie Dunn, Vice Dean of Research, and Professor of Molecular Genetics at the Donnelly Cell and Biomolecule Research Center has developed synthetic antibodies as a promising treatment for diabetics. .. Retinopathy causes blindness and affects about 30% of diabetics.

Researchers tested antibodies on both Cell culture And the mouse, and the diary EMBO molecular medicine We announced the results today. “This study shows that these are antibody A very attractive remedy for restoring the blood-retina barrier “It gives new hope for the treatment of eye diseases such as diabetic retinopathy and macular degeneration,” said Rony Chidiac, a postdoctoral fellow in the Angers lab and the lead author of the study………..

Read more: https://floridanewstimes.com/new-antibody-therapies-may-improve-diabetic-retinopathy-and-other-eye-conditions/282576/

Source: Floridan News Times

Newsletter Sign-up

  • This field is for validation purposes and should be left unchanged.